Why Is ARROWHEAD PHARMACEUT (ARWR) Stock Moving Today?

Why ARWR stock is moving today

Arrowhead Pharmaceuticals stock is moving lower today, down 4.5% over the last eight sessions to $85.11 from $89.12. The decline follows recent insider sales and a mixed backdrop of analyst optimism and deteriorating short-term sentiment. The stock is trading within its 52-week range of $27.10 to $95.49 but has struggled to maintain upward momentum.

What Happened

Two directors at Arrowhead Pharmaceuticals recently sold shares, with Perry Michael S selling 11,600 shares for $1 million on August 18. The sales occurred as the stock price surged but have since contributed to a downward trend. Additional insider sales by Olukotun Adeoye Y on the same date were reported in SEC filings. These moves come amid a broader pattern of insider activity, with no buys recorded in the last 90 days and two sells totaling $1.2 million. Meanwhile, Donald J. Trump sold between $100,001 and $250,000 in undisclosed holdings on February 9.

What The Data Shows

The stock has moved -4.5% over the last eight sessions, reflecting a recent pullback from recent highs. Despite positive developments including the EU authorization of REDEMPLO for Familial Chylomicronaemia Syndrome and upcoming data presentations on Plozasiran, the stock has failed to sustain gains. Analysts remain optimistic, with HC Wainwright & Co. and RBC Capital maintaining Buy and Outperform ratings, respectively. However, sentiment has deteriorated over the past seven days, with a score of 50/100 compared to a 30-day average of 60/100.

What To Watch

Arrowhead Pharmaceuticals does not have an upcoming earnings date disclosed. Investors should monitor coverage breadth and analyst reactions to its upcoming data presentations at the European Society of Cardiology Congress for potential catalysts.